Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Accumulated Expenses (2016 - 2021)

Sunshine Biopharma's Accumulated Expenses history spans 8 years, with the latest figure at $48287.0 for Q4 2021.

  • For Q4 2021, Accumulated Expenses rose 213.71% year-over-year to $48287.0; the TTM value through Dec 2021 reached $48287.0, up 213.71%, while the annual FY2021 figure was $48287.0, 213.71% up from the prior year.
  • Accumulated Expenses reached $48287.0 in Q4 2021 per SBFM's latest filing, down from $84945.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $84945.0 in Q3 2021 to a low of $1171.0 in Q1 2017.
  • Average Accumulated Expenses over 5 years is $29464.0, with a median of $28407.5 recorded in 2018.
  • Peak YoY movement for Accumulated Expenses: crashed 67.11% in 2017, then soared 1772.25% in 2018.
  • A 5-year view of Accumulated Expenses shows it stood at $9215.0 in 2017, then rose by 0.82% to $9291.0 in 2018, then surged by 66.92% to $15509.0 in 2019, then decreased by 0.75% to $15392.0 in 2020, then surged by 213.71% to $48287.0 in 2021.
  • Per Business Quant, the three most recent readings for SBFM's Accumulated Expenses are $48287.0 (Q4 2021), $84945.0 (Q3 2021), and $58712.0 (Q2 2021).